Novan.com isn't just a website—it's the digital front door to a pharmaceutical phoenix, rising from the ashes of a failed COVID-19 treatment to chase a $10B+ dermatology market with a $210M war chest.

"This isn't a biotech startup—it's a $210M corporate resurrection with a dermatology obsession."

The website itself tells a story of transition. Novan.com redirects to Pelthos.com, but the domain still exists—like a digital ghost of the company's past. The tech stack (jQuery, Bootstrap, Vite) is functional but not cutting-edge, suggesting they're prioritizing clinical execution over digital polish. Meanwhile, their executive team reads like a dermatology dream team: a COO from the trenches, a translational science VP, a CMO who knows drug development, and a sales leader embedded in their subsidiary ecosystem.

• FDA-approved berdazimer gel for molluscum contagiosum—immediate revenue driver
• Subsidiary structure (Journey Medical Corporation) creates a built-in commercialization engine
• Dermatology focus avoids the R&D quagmire that killed their COVID-19 bet
• Lean 53-person team suggests asset-light, partnership-driven growth